RxDoctor Payments Data

Rami Alashram

Pulmonary Disease · Kettering, OHNPI 1437481793

Payments from drug & device makers

$6,554in general payments, 2019–2025

Across 33 payments — averaging $198.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$6K
  • GSK$136
  • Johnson & Johnson$103
  • Genentech USA, Inc.$100
  • Pulmonx Corporation$30
  • Sanofi$26

What the payments were for

  • Travel & lodging$1,67326%
  • Food & beverage$78212%
  • Education$4,10063%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,554 in reported general payments places this provider in the 70th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$152,023
Medicare patients
520
Services billed
1,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter426$308,713
Spiriva RespimatTiotropium Bromide172$115,311
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr171$93,017
Breo ElliptaFluticasone/Vilanterol178$83,514
Breztri AerosphereBudesonide/Glycopyr/Formoterol61$54,109
Stiolto RespimatTiotropium Br/Olodaterol Hcl34$26,246
SymbicortBudesonide/Formoterol Fumarate52$14,763
Advair HfaFluticasone Propion/Salmeterol32$14,353
Bevespi AerosphereGlycopyrrolate/Formoterol Fum18$13,945
Albuterol Sulfate HfaAlbuterol Sulfate592$13,678
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate92$12,364
EliquisApixaban13$11,015
Combivent RespimatIpratropium/Albuterol Sulfate15$9,804
DuleraMometasone/Formoterol19$8,978
Fluticasone-SalmeterolFluticasone Propion/Salmeterol64$7,440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$136$494,357806 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Kettering

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →